Search Results - "Sievers, Eric L"

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma by Senter, Peter D, Sievers, Eric L

“…Progress has been made recently in developing antibody-drug conjugates (ADCs) that can selectively deliver cancer drugs to tumor cells. In principle, the idea…”
Get full text

Antibody-Drug Conjugates in Cancer Therapy by Sievers, Eric L, Senter, Peter D

“…An antibody-drug conjugate (ADC) provides the possibility of selectively ablating cancer cells by combining the specificity of a monoclonal antibody (mAb) for…”
Get full text

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study by PRO, Barbara, ADVANI, Ranjana, YIN YANG, SIEVERS, Eric L, KENNEDY, Dana A, SHUSTOV, Andrei, BRICE, Pauline, BARTLETT, Nancy L, ROSENBLATT, Joseph D, ILLIDGE, Tim, MATOUS, Jeffrey, RAMCHANDREN, Radhakrishnan, FANALE, Michelle, CONNORS, Joseph M

“…Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug…”
Get full text

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial by Moskowitz, Craig H, Dr Prof, Nademanee, Auayporn, Prof, Masszi, Tamas, Prof, Agura, Edward, Prof, Holowiecki, Jerzy, Prof, Abidi, Muneer H, Prof, Chen, Andy I, Prof, Stiff, Patrick, Prof, Gianni, Alessandro M, Prof, Carella, Angelo, Prof, Osmanov, Dzhelil, Prof, Bachanova, Veronika, Prof, Sweetenham, John, Prof, Sureda, Anna, Prof, Huebner, Dirk, MD, Sievers, Eric L, MD, Chi, Andy, PhD, Larsen, Emily K, MS, Hunder, Naomi N, MD, Walewski, Jan, Prof

“…Summary Background High-dose therapy followed by autologous stem-cell transplantation is standard of care for patients with relapsed or primary refractory…”
Get full text

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma by YOUNES, Anas, GOPAL, Ajay K, FORERO-TORRES, Andres, MOSKOWITZ, Craig H, CONNORS, Joseph M, ENGERT, Andreas, LARSEN, Emily K, KENNEDY, Dana A, SIEVERS, Eric L, CHEN, Robert, SMITH, Scott E, ANSELL, Stephen M, ROSENBLATT, Joseph D, SAVAGE, Kerry J, RAMCHANDREN, Radhakrishnan, BARTLETT, Nancy L, CHESON, Bruce D, DE VOS, Sven

“…Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing…”
Get full text

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma by Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L., Younes, Anas

“…We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory…”
Get full text

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate by OKELEY, Nicole M, MIYAMOTO, Jamie B, XINQUN ZHANG, SANDERSON, Russell J, BENJAMIN, Dennis R, SIEVERS, Eric L, SENTER, Peter D, ALLEY, Stephen C

“…Purpose: SGN-35 is an antibody-drug conjugate (ADC) containing the potent antimitotic drug, monomethylauristatin E (MMAE), linked to the anti-CD30 monoclonal…”
Get full text

A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma by Forero‐Torres, Andres, Leonard, John P., Younes, Anas, Rosenblatt, Joseph D., Brice, Pauline, Bartlett, Nancy L., Bosly, Andre, Pinter‐Brown, Lauren, Kennedy, Dana, Sievers, Eric L., Gopal, Ajay K.

“…Summary SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin lymphoma (HL) and anaplastic…”
Get full text

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia by Sekeres, Mikkael A, Lancet, Jeffrey E, Wood, Brent L, Grove, Laurie E, Sandalic, Larissa, Sievers, Eric L, Jurcic, Joseph G

“…Improving outcomes in older adults with acute myeloid leukemia remains a formidable challenge. Lintuzumab (SGN-33; HuM195) is a humanized monoclonal antibody…”
Get full text

Incentivized self-vaccination for global measles eradication by Sievers, Benjamin L., Sievers, Robert E., Sievers, Eric L.

“…Measles–we've become inured to its cruel, insidious impact as it kills over 100,000 children yearly because of suboptimal vaccination coverage. It does not…”
Get full text

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma by THOMPSON, John A, CURTI, Brendan D, REDMAN, Bruce G, BHATIA, Shailender, WEBER, Jeffrey S, AGARWALA, Sanjiv S, SIEVERS, Eric L, HUGHES, Steven D, DEVRIES, Todd A, HAUSMAN, Diana F

“…A phase I study of patients with metastatic malignant melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD),…”
Get full text

A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders by DUVIC, Madeleine, REDDY, Sunil A, PINTER-BROWN, Lauren, KORMAN, Neil J, ZIC, John, KENNEDY, Dana A, LORENZ, Jennie, SIEVERS, Eric L, KIM, Youn H

“…Purpose: An open-label, multicenter, phase II study was conducted to define the safety and antitumor activity of the monoclonal antibody SGN-30 in patients…”
Get full text

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy by Rajvanshi, Pankaj, Shulman, Howard M., Sievers, Eric L., McDonald, George B.

“…Gemtuzumab ozogamicin (Mylotarg) targets leukemia cells expressing the CD33 receptor by means of a monoclonal antibody conjugated to a cytotoxic agent,…”
Get full text

Safety and Efficacy of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group by APLENC, Richard, ALONZO, Todd A, SIEVERS, Eric L, ARCECI, Robert J, GERBING, Robert B, LANGE, Beverly J, HURWITZ, Craig A, WELLS, Robert J, BERNSTEIN, Irwin, BUCKLEY, Patrick, KRIMMEL, Kathleen, SMITH, Franklin O

“…While gemtuzumab ozogamicin (GTMZ) is commonly used in the treatment of acute myeloid leukemia (AML) in combination with standard chemotherapy agents, the…”
Get full text

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas by Younes, Anas, Bartlett, Nancy L, Leonard, John P, Kennedy, Dana A, Lynch, Carmel M, Sievers, Eric L, Forero-Torres, Andres

“…Brentuximab vedotin is a drug immunoconjugate with an antibody targeting CD30, an antigen expressed mainly on Hodgkin's and anaplastic large-cell lymphomas,…”
Get full text

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin by Linenberger, Michael L., Hong, Tom, Flowers, David, Sievers, Eric L., Gooley, Ted A., Bennett, John M., Berger, Mark S., Leopold, Lance H., Appelbaum, Frederick R., Bernstein, Irwin D.

“…Expression of multidrug resistance (MDR) features by acute myeloid leukemia (AML) cells predicts a poor response to many treatments. The MDR phenotype often…”
Get full text

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies by Ansell, Stephen M, Maris, Michael B, Lesokhin, Alexander M, Chen, Robert W, Flinn, Ian W, Sawas, Ahmed, Minden, Mark D, Villa, Diego, Percival, Mary-Elizabeth M, Advani, Anjali S, Foran, James M, Horwitz, Steven M, Mei, Matthew G, Zain, Jasmine, Savage, Kerry J, Querfeld, Christiane, Akilov, Oleg E, Johnson, Lisa D S, Catalano, Tina, Petrova, Penka S, Uger, Robert A, Sievers, Eric L, Milea, Anca, Roberge, Kathleen, Shou, Yaping, O'Connor, Owen A

“…TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 "don't eat me" signal. This first-in-human phase…”
Get full text

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding by Petrova, Penka S, Viller, Natasja Nielsen, Wong, Mark, Pang, Xinli, Lin, Gloria H Y, Dodge, Karen, Chai, Vien, Chen, Hui, Lee, Vivian, House, Violetta, Vigo, Noel T, Jin, Debbie, Mutukura, Tapfuma, Charbonneau, Marilyse, Truong, Tran, Viau, Stephane, Johnson, Lisa D, Linderoth, Emma, Sievers, Eric L, Maleki Vareki, Saman, Figueredo, Rene, Pampillo, Macarena, Koropatnick, James, Trudel, Suzanne, Mbong, Nathan, Jin, Liqing, Wang, Jean C Y, Uger, Robert A

“…The ubiquitously expressed transmembrane glycoprotein CD47 delivers an anti-phagocytic (do not eat) signal by binding signal-regulatory protein α (SIRPα) on…”
Get full text

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies by FANALE, Michelle A, FORERO-TORRES, Andres, ROSENBLATT, Joseph D, ADVANI, Ranjana H, FRANKLIN, AnnaR, KENNEDY, Dana A, HAN, Tae H, SIEVERS, Eric L, BARTLETT, Nancy L

“…The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl…”
Get full text

Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia by Sutherland, May Kung, Yu, Changpu, Lewis, Timothy S., Miyamoto, Jamie B., Morris-Tilden, Carol A., Jonas, Mechthild, Sutherland, Jennifer, Nesterova, Albina, Gerber, Hans-Peter, Sievers, Eric L., Grewal, Iqbal S., Law, Che-Leung

“…Despite therapeutic advances, the long-term survival rates for acute myeloid leukemia (AML) are estimated to be 10% or less, pointing to the need for better…”
Get full text